These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29338294)

  • 21. Toxic Epidermal Necrolysis Related to Paliperidone Palmitate: First Case Report.
    Struye A; Depuydt C; Abdel Sater E; Dubois V
    J Clin Psychopharmacol; 2016 Jun; 36(3):279-82. PubMed ID: 26928057
    [No Abstract]   [Full Text] [Related]  

  • 22. [Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs].
    Seigneurie AS; Sauvanaud F; Limosin F
    Encephale; 2016 Jun; 42(3):248-54. PubMed ID: 26922134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.
    Ravenstijn P; Remmerie B; Savitz A; Samtani MN; Nuamah I; Chang CT; De Meulder M; Hough D; Gopal S
    J Clin Pharmacol; 2016 Mar; 56(3):330-9. PubMed ID: 26189570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tardive dyskinesia induced by a switch from haloperidol depot to paliperidone palmitate.
    Hsu CY; Lin YH; Shen YC
    J Neuropsychiatry Clin Neurosci; 2013; 25(4):E46-7. PubMed ID: 24247889
    [No Abstract]   [Full Text] [Related]  

  • 25. Case Report: Paliperidone Palmitate, But Not Aripiprazole, as a Possible Risk Factor for Pulmonary Embolism.
    Michaud I; Landry P
    J Clin Psychopharmacol; 2018 Aug; 38(4):392-394. PubMed ID: 29746335
    [No Abstract]   [Full Text] [Related]  

  • 26. Paliperidone induced neutropenia in first episode psychosis: a case report.
    Martos N; Hall W; Marhefka A; Sedlak TW; Nucifora FC
    BMC Psychiatry; 2021 Feb; 21(1):76. PubMed ID: 33549083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.
    Mauri MC; Reggiori A; Paletta S; Di Pace C; Altamura AC
    Expert Opin Drug Saf; 2017 Mar; 16(3):365-379. PubMed ID: 28140680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tardive Tourette-like syndrome in a patient treated with paliperidone.
    Fountoulakis KN; Panagiotidis P
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):E35-6. PubMed ID: 22231343
    [No Abstract]   [Full Text] [Related]  

  • 29. Dose-Dependent Paliperidone Associated With Angioedema.
    Yucel A; Yucel N; Ozcan H; Saritemur M
    J Clin Psychopharmacol; 2015 Oct; 35(5):615-6. PubMed ID: 26125544
    [No Abstract]   [Full Text] [Related]  

  • 30. Early-onset tardive dyskinesia in a neuroleptic-naive patient exposed to paliperidone.
    Hsu WY; Chiu NY
    J Clin Psychopharmacol; 2013 Oct; 33(5):712-3. PubMed ID: 23899637
    [No Abstract]   [Full Text] [Related]  

  • 31. Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.
    Morris MT; Tarpada SP
    Psychopharmacol Bull; 2017 May; 47(2):42-52. PubMed ID: 28626271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Angioedema Associated With Long-Acting Injectable Paliperidone Palmitate: A Case Report.
    Papadopoulou A; Gkikas K; Efstathiou V; Gkikas I; Kokoris S; Lagari V; Papageorgiou C; Douzenis A; Siafakas N; Rizos EN
    J Clin Psychopharmacol; 2017 Dec; 37(6):730-732. PubMed ID: 29028688
    [No Abstract]   [Full Text] [Related]  

  • 33. Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling D; Schooler N; Lindenmayer JP; Canuso C; Alphs L
    J Clin Psychopharmacol; 2016 Aug; 36(4):372-6. PubMed ID: 27322760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic drug evaluation of paliperidone in the treatment of schizoaffective disorder.
    Macaluso M; Oliver H; Sohail Z
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):871-879. PubMed ID: 28675307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paliperidone-induced rhabdomyolysis: a case report.
    Fernández-Macho JG; Espárrago-Llorca G; Morales-Gómez GR; Guisado-Macías JA
    Actas Esp Psiquiatr; 2015; 43(2):66-8. PubMed ID: 25812544
    [No Abstract]   [Full Text] [Related]  

  • 36. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia.
    Hauser RA; Factor SA; Marder SR; Knesevich MA; Ramirez PM; Jimenez R; Burke J; Liang GS; O'Brien CF
    Am J Psychiatry; 2017 May; 174(5):476-484. PubMed ID: 28320223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case of catatonia associated with paliperidone.
    Tu CY; Chien YL; Huang WL
    Psychiatry Clin Neurosci; 2016 Aug; 70(8):366. PubMed ID: 27241961
    [No Abstract]   [Full Text] [Related]  

  • 38. Mortality rate is associated with paliperidone palmitate, risperidone long-acting injection, and oral paliperidone administration.
    Suzuki H; Hibino H; Inoue Y; Takaya A
    Asian J Psychiatr; 2018 Jun; 35():28. PubMed ID: 29751217
    [No Abstract]   [Full Text] [Related]  

  • 39. Predicting psychotic relapse following paliperidone discontinuation.
    Suzuki T
    Lancet Psychiatry; 2023 Mar; 10(3):157-158. PubMed ID: 36804062
    [No Abstract]   [Full Text] [Related]  

  • 40. Paliperidone Palmitate-Induced Delirium in an Adolescent with Schizophrenia: Case report.
    Mirza H; Harding D; Al-Balushi N
    Sultan Qaboos Univ Med J; 2018 May; 18(2):e208-e210. PubMed ID: 30210852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.